Multiple sclerosis (MS) is a debilitating autoimmune disorder. Currently, there is a lack of
effective treatment for the progressive form of MS, partly due to insensitive readout for …

The degeneration and dysfunction of neurons are key features of neurodegenerative
diseases (NDs). Currently, one of the main challenges facing researchers and clinicians is …

The locus coeruleus is the initial site of Alzheimer's disease neuropathology, with
hyperphosphorylated Tau appearing in early adulthood followed by neurodegeneration in …

Sensitive and reliable protein biomarkers are needed to predict disease trajectory and
personalize treatment strategies for multiple sclerosis (MS). Here, we use the highly …

Neuroinflammatory and neurodegenerative diseases are characterized by the interplay of a
number of molecular pathways that can be assessed through biofluids, especially …

Background There is a need for biomarkers to support an accurate diagnosis of Parkinson's
disease (PD). Cerebrospinal fluid (CSF) has been a successful biofluid for finding …

Oncostatin M (OSM) is an IL-6 family member which exerts neuroprotective and
remyelination-promoting effects after damage to the central nervous system (CNS) …

The advent of highly effective disease modifying therapy has transformed the landscape of
multiple sclerosis (MS) care over the last two decades. However, there remains a critical …

Multiple sclerosis (MS) is the inflammatory demyelinating and neurodegenerative disease of
the central nervous system (CNS) that affects approximately 2.8 million people worldwide. In …

Background Neuroinflammation is a response that involves different cell lineages of the
central nervous system, such as neurons and glial cells. Among the non-pharmacological …